# Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Idiopathic Recurrent Pericarditis

> **NCT04692766** · PHASE2,PHASE3 · COMPLETED · sponsor: **R-Pharm International, LLC** · enrollment: 20 (actual)

## Conditions studied

- Pericarditis

## Interventions

- **BIOLOGICAL:** RPH-104
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04692766
- **Lead sponsor:** R-Pharm International, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-12
- **Primary completion:** 2022-01-24
- **Final completion:** 2022-03-22
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2022-10-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04692766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04692766, "Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Idiopathic Recurrent Pericarditis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04692766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*